Following subcutaneous administration, risankizumab is absorbed into the circulation with a time to maximum concentration of 5 to 7 days. As an IgG1 monoclonal antibody, its systemic disposition is described by a two-compartment model with dose- and time-independent parameters, with no apparent target-mediated disposition — consistent with IL-23 being present at low picomolar concentrations in tissue and therefore insufficient to drive nonlinear clearance. Subcutaneous delivery is efficient: cross-study population pharmacokinetic modeling in psoriasis estimated an absolute subcutaneous bioavailability of 89% for the phase III regimen (150 mg at weeks 0 and 4, then every 12 weeks), supporting reliable attainment of therapeutically relevant exposure across the dosing interval. Overall, risankizumab displays linear, time-independent pharmacokinetics without evidence of accumulation or saturable elimination.

IL-23 p19 binding and selective blockade. Risankizumab targets the p19 subunit of IL-23, which is unique to IL-23 and absent from IL-12. By binding p19, the antibody inhibits IL-23 from interacting with the IL-23 receptor, preventing receptor complex assembly and downstream signaling initiation. Biophysical characterization confirms the interaction is of exceptionally high affinity, with a dissociation constant (Kd) below 10 pM. Crucially, the antibody shows no binding of the shared IL-12/23 p40 subunit at concentrations up to 1.2 µM, meaning IL-12–driven Th1 responses remain intact. Surface plasmon resonance experiments demonstrate that risankizumab competitively inhibits IL-23 binding to the IL23Rα subunit in a manner expected for an antibody that occludes the p19/IL23Rα interface. Kinetic comparisons show that comparator antibodies have off-rates 8 to 10-fold faster than risankizumab, supporting sustained target occupancy between maintenance doses.

Receptor blockade and JAK–STAT cascade interruption. Engagement of the IL-23 receptor normally triggers JAK2 and TYK2 activation, leading to phosphorylation of STAT3 and STAT4 — the transcription factors that drive Th17 differentiation and sustain pathogenic effector programs. By preventing receptor assembly, risankizumab blocks IL-23–dependent cell signaling and the release of proinflammatory cytokines, placing the inhibitory event upstream of the entire STAT-driven transcriptional cascade. Disruption here is functionally broad: STAT3 activation normally promotes transcription of RORγt and subsequent IL-17A, IL-17F, and IL-22 gene programs, all of which become attenuated when the initiating receptor–ligand event is blocked.

Th17-axis gene expression. Downstream of JAK–STAT disruption, risankizumab suppresses Th17-linked programs in affected tissues. In the absence of IL-23 signaling, Th17 cell development is arrested at an early activation stage, with a corresponding reduction in IL-17 production by stimulated Th17 lymphocytes. Pharmacodynamic analyses of psoriatic skin biopsies show that treatment is associated with significant reductions in IL-23/IL-17-axis gene expression, including coordinated decreases in IL23A, IL23R, IL17A, IL17F, and IL22. The effect is pathway-selective: IL-23 signaling was suppressed without significant changes in IFN-γ mRNA, confirming that the IL-12/Th1 arm is spared — a mechanistic distinction versus ustekinumab, which blocks p40 and curtails both IL-23 and IL-12 signaling.

Parallel pathways. IL-23 drives inflammation through cell types beyond adaptive Th17 cells. Group 3 innate lymphoid cells (ILC3s) respond to IL-23 by producing IL-17 and IL-22 directly at barrier surfaces, amplifying tissue inflammation through innate IL-17 and IL-22 output. IL-23 also acts on γδ T cells to stimulate innate-source IL-17 production independently of adaptive Th17 differentiation. Additionally, IL-23 can counteract immune resolution by inhibiting regulatory T cell function. By neutralizing IL-23, risankizumab interrupts all three of these parallel inflammatory arms simultaneously.

Translation to clinical efficacy. The molecular events above converge on measurable disease suppression. Exposure–response modeling confirmed that maximum efficacy is achieved with the approved regimen without an apparent exposure–safety relationship. In head-to-head trials in plaque psoriasis, selective IL-23 blockade produced superior PASI 90 responses versus ustekinumab, illustrating the functional consequence of p19 versus p40 selectivity. In Crohn's disease, the mechanistic link between pathway inhibition and tissue healing is supported by the finding that changes in fecal calprotectin and lactoferrin correlated with changes in endoscopic disease severity, grounding the molecular mechanism in clinically actionable endpoints.